treatment. Further, the therapy may prevent or reduce the adverse events and side-effects associated with conventional therapies, so that the therapy may be better tolerated than conventional therapies, such as risperidone or aripiprazole treatment.

[0007a] In one aspect, the present disclosure refers to a pharmaceutical composition comprising cannabidiol (CBD) and Δ^9-tetrahydrocannabinol (THC) in a ratio of CBD:THC from 4:1 to 1:4, one or more terpene or terpenoid compounds and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof.

[0007b] In another aspect, the present disclosure refers to a use of the pharmaceutical composition as disclosed herein in the manufacture of a medicament for treating autism.

[0007c] In another aspect, the present disclosure refers to a use of the pharmaceutical composition as disclosed herein, in the manufacture of a medicament for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof.

[0007d] In another aspect, the present disclosure refers to a kit comprising in separate parts: (a) CBD, and (b) THC, wherein the amount of CBD in part (a) and the amount of THC in part (b) are in a ratio of CBD:THC from 4:1 to 1:4, wherein at least one of (a) and (b) comprises one or more terpene or terpenoid compounds.

[0007e] In another aspect, the present disclosure refers to an agent for treating autism comprising CBD and THC in a ratio of CBD:THC from 4:1 to 1:4 and one or more terpene or terpenoid compounds.

[0007f] In another aspect, the present disclosure refers to a use of the agent as disclosed herein in the manufacture of a medicament for treating autism.

[0008] In one example, there is provided a pharmaceutical composition comprising CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1 and optionally one or more pharmaceutically acceptable excipient(s).

[0009] In another example, there is provided a method for treating autism comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of the disclosure.

[0010] In a further example, there is provided a method for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition of the disclosure.

[0011] In still a further example, there is provided use of CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1 in the manufacture of a medicament for treating autism.

[0012] In yet another example, there is provided use of CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1 in the manufacture of a medicament for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof.

[0013] In another example, there is provided a pharmaceutical composition comprising CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1 for treating autism.

[0014] In a further example, there is provided a pharmaceutical composition comprising CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1 for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof.

[0015] In yet another example, there is provided a kit comprising in separate parts: (a) CBD, and (b) THC, wherein the amount of CBD in part (a) and the amount of THC in part (b) are in a ratio of CBD:THC from about 0.1:5 to about 5:0.1.

[0016] In still another example, there is provided an agent for treating autism comprising CBD and THC in a ratio of CBD:THC from about 0.1:5 to about 5:0.1.

Brief Description of Drawings

[0017] The present application will be further described, by way of example only, with reference to the accompanying drawings, in which:

Figure 1 shows a graphic outlining interactions of the CB_1 and CB_2 receptors as part of the human endocannabinoid system.

Figure 2 shows a graphic of the human brain indicating regions of high and moderate CB_1 receptor expression. Regions with high CB_1 expression include the cerebral cortex, cerebellum, hippocampus, basal ganglia and prefrontal cortex. Regions with moderate CB_1 expression include hypothalamus, periaqueductal gray, nucleus of the solitary tract, spinal cord, brain stem and amygdala.

Figure 3 shows a pie chart showing the initial severity of ASD in the patients included in the study of Example 2.

Figure 4 shows a chart of CGI-I scores post-treatment in the patients included in the study of Example 2.

Description of Embodiment(s)

[0018] Before describing the present invention in detail, it is to be understood that this invention is not limited to particularly exemplified pharmaceutical compositions, methods of production or treatment, which may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only, and is not intended to be limiting.

[0019] The inventions described and claimed herein have many attributes and embodiments including, but not limited to, those set forth or described or referenced in this summary section, which is not intended to be all-inclusive. The inventions described and claimed herein are not limited to or by the features or embodiments identified in this summary section, which is included for purposes of overview illustration only and not limitation.

[0020] All publications, patents and patent applications cited herein, whether *supra* or *infra*, are hereby incorporated by reference in their entirety. However, publications mentioned herein

Claims

1. A pharmaceutical composition comprising cannabidiol (CBD) and Δ^9-tetrahydrocannabinol (THC) in a ratio of CBD:THC from 4:1 to 1:4, one or more terpene or terpenoid compounds and optionally one or more pharmaceutically acceptable carriers, diluents, adjuvants, excipients or any combination thereof.

2. The composition of claim 1, wherein the pharmaceutical composition comprises a *Cannabis* extract comprising the CBD and the THC.

3. The composition of claim 2, wherein the *Cannabis* extract further comprises the one or more terpenes and/or terpenoids.

4. The composition of claim 2 or 3, wherein the *Cannabis* extract is macerated oil or a resin.

5. The composition of claim 2 or 3, wherein the *Cannabis* extract is formed by alcohol extraction of *Cannabis* plant material.

6. The composition of claim 5, wherein the alcohol is ethanol.

7. The composition of claim 4 or 5, wherein the *Cannabis* plant material used to form the extract is dried prior to extraction.

8. The composition of any one of claims 1-7, further comprising cannabigerol.

9. The composition of any one of claims 1-8, wherein the composition is formulated for sublingual administration.

10. The composition of any one of claims 1-9, wherein the pharmaceutical composition is in the form of a liquid.

11. The composition of any one of claims 1-10, comprising a carrier selected from olive oil, hemp oil, sesame oil, coconut oil, vegetable oil, canola oil, grape seed oil, almond oil, medium-chain triglyceride (MCT) oil, or a combination thereof.

12. Use of the pharmaceutical composition according to any one of claims 1-11 in the manufacture of a medicament for treating autism.

13. Use of the pharmaceutical composition according to any one of claims 1-11, in the manufacture of a medicament for treating a symptom of autism or a symptom associated with autism selected from reduced sociability, tantrums, poor use of language, repetitive behaviour, self-injurious behaviour, irritability, hyperactivity, poor ability to focus, unexplained weight loss, fever, fatigue, pain, and skin changes or a combination thereof.

14. The use of claim 12 or 13, wherein treatment is maintained for at least about 12 weeks.

15. The use of any one of claims 12-14, wherein THC is to be administered in an amount of less than about 10 mg/day.

16. The use of any one of claims 12-15, wherein THC is to be administered in an amount from about 0.1-10 mg/day.

17. The use of any one of claims 12-16, wherein CBD is to be administered in an amount of less than about 20 mg/day.

18. The use of any one of claims 12-17, wherein CBD is to be administered in an amount from about 0.1-20 mg/day.

19. The use of any one of claims 12-18, wherein the pharmaceutical composition is to be administered twice daily.

20. The use of any one of claims 12-19, wherein the administration is sublingual administration.

21. A kit comprising in separate parts: (a) CBD, and (b) THC, wherein the amount of CBD in part (a) and the amount of THC in part (b) are in a ratio of CBD:THC from 4:1 to 1:4, wherein at least one of (a) and (b) comprises one or more terpene or terpenoid compounds.

22. An agent for treating autism comprising CBD and THC in a ratio of CBD:THC from 4:1 to 1:4 and one or more terpene or terpenoid compounds.

23. An agent according to claim 22, further comprising cannabigerol.

24. Use of the agent of claim 22 or 23 in the manufacture of a medicament for treating autism.